Biopharmaceutical company Hoth Therapeutics announced on October 9, 2025, an expansion of its AI strategy by signing a licensing agreement for the NVIDIA AI Enterprise software platform. This move gives the company access to NVIDIAs full stack of enterprise AI software, including specialized tools for drug development. Unlike purchasing hardware, the AI Enterprise license provides Hoth Therapeutics with a ready-made, optimized, and supported software environment for building and training its own machine learning models. The company plans to use these computational capabilities to accelerate its current programs in oncology and dermatology, specifically for deeper analysis of clinical trial data and the creation of predictive models. This move demonstrates the trend of smaller biotech companies adopting advanced AI platforms to increase R&D efficiency.
Hoth Therapeutics Expands AI Initiative by Licensing NVIDIA AI Enterprise Platform
